Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Neurognostics question. Richard Caton V.

Fine EJ, Fine DL.

J Hist Neurosci. 2012;21(4):427-8, 434-8. doi: 10.1080/0964704X.2012.659119. No abstract available.

PMID:
22947383
2.

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Apr 19;28(18):3143-51. doi: 10.1016/j.vaccine.2010.02.056. Epub 2010 Mar 1.

3.

Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Jan 22;28(4):1031-40. doi: 10.1016/j.vaccine.2009.10.126. Epub 2009 Nov 13.

4.

A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).

Fine DL, Jenkins E, Martin SS, Glass P, Parker MD, Grimm B.

J Virol Methods. 2010 Feb;163(2):424-32. doi: 10.1016/j.jviromet.2009.11.006. Epub 2009 Nov 10.

5.

Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Martin SS, Bakken RR, Lind CM, Reed DS, Price JL, Koeller CA, Parker MD, Hart MK, Fine DL.

Vaccine. 2009 Nov 16;27(49):6814-23. doi: 10.1016/j.vaccine.2009.09.013. Epub 2009 Sep 15.

6.

Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.

Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV.

Vaccine. 2008 Jun 25;26(27-28):3497-506. doi: 10.1016/j.vaccine.2008.04.044. Epub 2008 May 7.

PMID:
18508163
7.

Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.

Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, Baker DC, Powers AM, Bowen RA.

Vaccine. 2007 Feb 26;25(10):1868-76. Epub 2006 Oct 27.

PMID:
17240002
8.

The contributions of Dr. Roswell Park to epilepsy and spinal surgery.

Fine EJ, Reynolds D, Soria ED, Scalcione LR, Fine DL.

Neurosurgery. 1998 Feb;42(2):372-7; discussion 377-8.

PMID:
9482189
9.

Contributions of the founders of Craig Colony to epileptology and public care of epileptics: 1890-1915.

Fine EJ, Fine DL, Sentz L, Soria ED.

J Hist Neurosci. 1995 Jun;4(2):77-100.

PMID:
11619021
10.

Three state health reform initiatives fail.

Glatfelter R, Fine DL, Wright N.

Health Syst Rev. 1994 Sep-Oct;27(5):14-21. No abstract available.

PMID:
10137363
11.

The importance of Spratling.

Fine EJ, Fine DL, Sentz L.

Arch Neurol. 1994 Jan;51(1):82-6.

PMID:
8274114
12.

William P. Letchworth: philanthropist and pioneer epileptologist.

Fine EJ, Fine DL, Sentz L, Soria E.

Arch Neurol. 1993 Mar;50(3):313-6.

PMID:
8442713
13.

New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity.

Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH, Boyd MR.

J Natl Cancer Inst. 1989 Apr 19;81(8):577-86. Erratum in: J Natl Cancer Inst 1989 Jun 21;81(12):963.

PMID:
2495366
14.

Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice.

McLemore TL, Eggleston JC, Shoemaker RH, Abbott BJ, Bohlman ME, Liu MC, Fine DL, Mayo JG, Boyd MR.

Cancer Res. 1988 May 15;48(10):2880-6.

15.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR.

Cancer Res. 1988 Feb 1;48(3):589-601.

16.

Development of human tumor cell line panels for use in disease-oriented drug screening.

Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG, Boyd MR.

Prog Clin Biol Res. 1988;276:265-86. Review. No abstract available.

PMID:
3051021
17.

Metastasis models for human tumors in athymic mice: useful models for drug development.

Fine DL, Shoemaker R, Gazdar A, Mayo JG, Fodstad O, Boyd MR, Abbott BJ, Donovan PA.

Cancer Detect Prev Suppl. 1987;1:291-9.

PMID:
3480056
18.

Mason-Pfizer monkey virus and simian AIDS.

Fine DL.

Lancet. 1984 Feb 11;1(8372):335. No abstract available.

PMID:
6141397
19.

Expression of natural antibodies against endogenous and horizontally transmitted macaque retroviruses in captive primates.

Fine DL, Arthur LO.

Virology. 1981 Jul 15;112(1):49-61. No abstract available.

PMID:
6166123
20.

Functionally conserved determinants on gp70s of endogenous primate retroviruses.

Fine DL, Arthur LO, Schochetman G.

Virology. 1980 Feb;101(1):176-84. No abstract available.

PMID:
6153486
21.

Characterization of infection and replication of Mason-Pfizer monkey virus in human cell cultures.

Fine DL, Clarke GC, Arthur LO.

J Gen Virol. 1979 Aug;44(2):457-69.

PMID:
118235
23.
24.

Immunological characterization of the low-molecular-weight DNA binding protein of mouse mammary tumor virus.

Arthur LO, Long CW, Smith GH, Fine DL.

Int J Cancer. 1978 Oct 15;22(4):433-40.

PMID:
81189
25.

Prevalence of murine mammary tumor virus antibody and antigens in normal and tumor-bearing feral mice.

Fine DL, Arthur LO, Gardner MB.

J Natl Cancer Inst. 1978 Aug;61(2):485-91.

PMID:
210292
26.

Mouse mammary tumor virus and murine leukemia virus cell surface antigens on virus producer and nonproducer mammary epithelial tumor cells.

Schochetman G, Fine DL, Massey RJ.

Virology. 1978 Jul 15;88(2):379-83. No abstract available.

PMID:
211719
27.

Natural distribution of squirrel monkey retrovirus proviral sequences in primate DNAs.

Schochetman G, Fine DL.

J Gen Virol. 1978 Jul;40(1):257-61.

PMID:
99487
28.

Coexistence of the mouse mammary tumor virus (MMTV) major glycoprotein and natural antibodies to MMTV in sera of mammary tumor-bearing mice.

Arthur LO, Bauer RF, Orme LS, Fine DL.

Virology. 1978 Jun 15;87(2):266-75. No abstract available.

PMID:
208275
29.

Type D retroviruses: occurrence of natural antibodies to Mason-Pfizer monkey virus in rhesus monkeys.

Fine DL, Devare SG, Arthur LO, Charman HP, Stephenson JR.

Virology. 1978 May 15;86(2):567-71. No abstract available.

PMID:
78569
30.

Isolation of separate precursor polypeptides for the mouse mammary tumor virus glycoproteins and nonglycoproteins.

Schochetman G, Long CW, Oroszlan S, Arthur L, Fine DL.

Virology. 1978 Mar;85(1):168-74. No abstract available.

PMID:
206000
31.
32.

Oncogenicity of murine mammary tumor virus produced in tissue culture: brief communication.

Arthur LO, Fine DL, Bentvelzen P.

J Natl Cancer Inst. 1978 Feb;60(2):461-4.

PMID:
202721
36.

Cellular hypersensitivity of gp55 of RIII-murine mammary tumor virus and gp55-like protein of human breast cancers.

Black MM, Zachrau RE, Dion AS, Shore B, Fine DL, Leis HP Jr, Williams CJ.

Cancer Res. 1976 Nov;36(11 Pt 1):4137-42.

37.

Cell culture factors influencing in vitro expression of mouse mammary tumor virus.

Fine DL, Arthur LO, Young LJ.

In Vitro. 1976 Oct;12(10):693-701.

PMID:
65318
38.
39.
41.

Immunological relationship between an oncornavirus isolate from HEp-2 cells, Mason-Pfizer monkey virus, and human tumor cells.

Priori ES, Ilyin KV, Dmochowski L, Fine DL.

Bibl Haematol. 1975 Oct;(43):488-90. No abstract available.

PMID:
822825
42.

Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus materials.

Fine DL, Landon JC, Pienta RJ, Kubicek MT, Valerio MG, Loeb WF, Chopra HC.

J Natl Cancer Inst. 1975 Mar;54(3):651-8.

PMID:
804565
43.

In vitro system for production of mouse mammary tumor virus.

Fine DL, Arthur LO, PLOWMAN JK, Hillman EA, Klein F.

Appl Microbiol. 1974 Dec;28(6):1040-6.

44.
45.

Enhanced production of mouse mammary tumor virus in dexamethasone-treated, 5-iododeoxyuridine-stimulated mammary tumor cell cultures.

Fine DL, Plowman JK, Kelley SP, Arthur LO, Hillman EA.

J Natl Cancer Inst. 1974 Jun;52(6):1881-6. No abstract available.

PMID:
4134501
46.

Biologic characteristics of transformed rhesus foreskin cells infected with Mason-Pfizer monkey virus.

Fine DL, Peinta RJ, Malan LB, Kubicek MT, Bennett DG, Landon JC, Valerio MG, West DM, Fabrizio DA, Chopra HC.

J Natl Cancer Inst. 1974 Apr;52(4):1135-42. No abstract available.

PMID:
4207874
47.

Virus susceptibility of a new simian cell line of fetal origin.

Kubicek MT, Fine DL, Bennett DG, Malan LB, West DM, Holloway AM.

Appl Microbiol. 1973 Feb;25(2):275-8.

48.

Simian tumour virus proliferation in inoculated Macaca mulatta.

Fine DL, Kingsbury EW, Valerio MG, Kubicek MT, Landon JC, Chopra HC.

Nat New Biol. 1972 Aug 9;238(84):191-2. No abstract available.

PMID:
4626248
49.

Transformation of rhesus foreskin cells by Mason-Pfizer monkey virus.

Pienta RJ, Fine DL, Hurt T, Smith CK, Landon JC, Chopra HC.

J Natl Cancer Inst. 1972 Jun;48(6):1913-7. No abstract available.

PMID:
4626796
50.

Development of herpes simplex virus in the isolated nuclei of HEp-2 cells. I. Viability of isolated HSV-infected nuclei.

Fine DL, Ludwig EH.

Can J Microbiol. 1972 Mar;18(3):333-7. No abstract available.

PMID:
4341525

Supplemental Content

Support Center